exploring durvalumab bevacizumab tace in hepatocellular carcinoma: emerald-1 insights
Published 4 months ago • 164 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:34
emerald-1: durvalumab, bevacizumab and tace in unresectable hcc
-
2:09
safey findings of emerald-1: durvalumab, bevacizumab and tace in hcc
-
0:51
emerald-1 trial: improved pfs w/ durvalumab bevacizumab tace vs tace in hepatocellular carcinoma
-
1:03
phase iii emerald-1: bevacizumab and durvalumab with tace improves pfs in unresectable hcc
-
7:23
durvalumab plus bevacizumab, added to tace, shows benefit for unresectable hepatocellular carcinoma
-
3:38
emerald-1 trial in hcc
-
2:33
emerald-3: tremelimumab durvalumab with or without lenvatinib combined with tace in hcc
-
1:15
montblanc: sequential or up-front durvalumab, tremelimumab, bevacizumab in unresectable hcc
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
1:27
takeaways in hepatocellular carcinoma at asco gi 2023
-
4:53
checkpoint inhibition in hepatocellular carcinoma
-
6:37
caspian trial: durvalumab and chemotherapy in es-sclc
-
4:03
results of phase ii trial comparing tace and sbrt for hepatocellular carcinoma
-
4:18
meet dr. albayda
-
0:52
drp-104 with durvalumab in fibrolamellar hepatocellular carcinoma
-
2:30
outcomes with multikinase inhibitors after progression on first-line atezolizumab-bevacizumab in hcc
-
4:03
real-world outcomes of patients with hcc treated with lenvatinib vs. atezolizumab plus bevacizumab
-
0:32
will atezolizumab and bevacizumab be the new soc in high-risk hcc?